N (% of age subgroup) |
229 (31.7%) |
494 (68.3%) |
81 (57.9%) |
59 (42.1%) |
253 (62.6%) |
151 (37.4%) |
Study centre, N (% within age and infection status subgroup) |
Freiburg (145 households) |
103 (45.0%) |
208 (42.1%) |
45 (55.6%) |
19 (32.2%) |
111 (43.9%) |
58 (38.4%) |
Heidelberg (49 households) |
23 (10.0%) |
73 (14.8%) |
7 (8.6%) |
13 (22.0%) |
26 (10.3%) |
22 (14.6%) |
Tübingen (99 households) |
68 (29.7%) |
150 (30.4%) |
19 (23.5%) |
14 (23.7%) |
87 (34.4) |
43 (28.5%) |
Ulm (48 households) |
35 (15.3%) |
63 (12.8%) |
10 (12.3%) |
13 (22.0%) |
29 (11.5%) |
28 (18.5%) |
Male, N (%) |
116 (50.7) |
236 (47.8) |
36 (44.4) |
31 (52.5) |
125 (49.4) |
81 (53.6) |
Age in years, median (Q1-Q3) |
43 (35-50) |
45 (39-50) |
16 (15-17) |
16 (14-17) |
7 (4-10) |
8 (5-11) |
Days between earliest household infection and T2, median (IQR) |
332 (315-366) |
332 (312-361) |
327 (314-350) |
350 (314-377) |
335 (313-358) |
340 (307-369) |
T2 Current health VAS score, median (IQR) |
92 (82-100) |
87 (80-95) |
96 (88-100) |
91 (80-100) |
100 (94-100) |
100 (94-100) |
Pre-existing conditions, N (% of age and infection status subgroup) |
85 (36.3%) |
181 (36.2%) |
13 (15.9%) |
9 (15.3%) |
15 (5.8%) |
21 (13.9%) |
Medication, N (% of age and infection status subgroup) |
86 (37.6%) |
168 (34.0%) |
4 (4.9%) |
6 (10.2%) |
8 (3.2%) |
8 (5.3%) |